Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PBF-509 + Spartalizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PBF-509||Taminadenant|NIR178||Adenosine Targeting 18||Taminadenant (PBF-509) binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 28582704).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02403193||Phase Ib/II||PBF-509 + Spartalizumab PBF-509||Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO)||Active, not recruiting|
|NCT03207867||Phase II||PBF-509 + Spartalizumab||A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma||Recruiting|